Body Pharm Selank 10

Researchers looking to buy Selank peptide in South Africa in 2026 can source Body Pharm Selank 10mg as a lyophilised research vial. ZAR pricing and supplier availability should be confirmed at the point of order rather than via aggregator listings, prices shift weekly and stock varies by distributor. JCSG.org-specific public ZAR pricing for this SKU is as of 12 May 2026.

Key Takeaways

• Body Pharm Selank 10mg is a lyophilised heptapeptide (CAS 129954-34-3) sold for research use only, with ≥98% HPLC purity and a 10 mg fill per vial
• The Pro-Gly-Pro tail extension confers peptidase resistance, extending functional half-life from minutes (native tuftsin) to hours in rodent models
• Three mechanistic pathways remain under investigation: GABAergic modulation without sedation, hippocampal BDNF upregulation, and tuftsin-derived immune signalling
• Selank is not scheduled under SAHPRA as of 2026; confirm institutional ethics clearance and compliance before procurement
• Lyophilised vials store at −20°C for 24 months; reconstituted solutions should be aliquoted and used within 30 days to avoid freeze-thaw degradation
• ZAR pricing runs roughly R800–R1,300 per vial across 2024–2026; pull live figures directly from the supplier at checkout

What Is Body Pharm Selank 10mg?

Body Pharm Selank 10mg is a lyophilised research-use-only heptapeptide vial containing 10 mg of the tuftsin-derived sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (CAS 129954-34-3), molecular weight 836.97 g/mol, specified at ≥98% HPLC purity per the Body Pharm Certificate of Analysis. The SKU is sold for in vitro and non-clinical investigation only.

The 10 mg fill is the standard research format across the category, matching the dose-per-vial offered by comparator suppliers such as JCSG.org. Batch-specific CoAs covering identity, purity, and residual solvents are typically released to institutional buyers on request rather than published on the open product page.

For broader mechanistic context, see the Selank peptide overview. For the closest structural and functional comparator within the Russian neuropeptide series, the Semax research peptide page covers the relevant ground.

Core specifications at a glance

Parameter	Value
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro
CAS number	129954-34-3
Molecular weight	836.97 g/mol
Fill	10 mg lyophilised powder
Purity spec	≥98% HPLC
Classification	Research-use-only

Selank vs Tuftsin: Why the Sequence Matters

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) engineered by appending a Pro-Gly-Pro tripeptide to the C-terminus of native tuftsin (Thr-Lys-Pro-Arg). That modification confers substantial resistance to plasma peptidases and extends functional plasma half-life from minutes (tuftsin) to hours in rodent models, because the proline residues sterically shield the scissile bonds that peptidases normally cleave.

Native tuftsin undergoes rapid cleavage by leucine aminopeptidase and other serum exopeptidases, truncating its window of CNS activity to a few minutes after parenteral administration. Proline residues resist cleavage by most mammalian peptidases, and the Pro-Gly-Pro extension shields the scissile bonds at both termini. Zozulya and colleagues characterised this stability profile in their 2001 CNS Drug Reviews monograph. Semenova T.P. and colleagues revisited the pharmacokinetic and behavioural consequences in the same journal in 2010, documenting prolonged anxiolytic and neurotrophic activity in rodents at doses where tuftsin alone is essentially inactive.

For a researcher designing a chronic dosing study, the practical implication is dose frequency. Tuftsin demands near-continuous infusion to maintain receptor occupancy. Selank tolerates intermittent intranasal or intraperitoneal administration while preserving downstream GABAergic and BDNF readouts. This is why the Selank peptide overview treats the heptapeptide as the canonical tuftsin analogue for behavioural neuroscience work. Comparative protocols frequently pair it with Semax research peptide (the ACTH(4-10) analogue with an analogous Pro-Gly-Pro stabilisation strategy) rather than with the parent tetrapeptide.

Mechanisms Under Investigation in 2026

Selank's preclinical profile clusters around three pathways: GABAergic potentiation, BDNF upregulation in the hippocampus, and tuftsin-derived immune signalling. All three remain anchored in pre-2020 experimental literature, with 2023–2026 work refining rather than overturning the underlying models. No approved human therapeutic indication exists for Selank in any jurisdiction as of 2026, and every dataset cited below derives from rodent or in vitro systems.

GABAergic modulation without sedation

Selank potentiates GABA-A receptor activity in rodent anxiety models, producing anxiolytic behavioural readouts at doses that do not impair locomotor or motor coordination endpoints. A 2010 study by Semenova T.P. and colleagues characterised this dissociation between anxiolysis and sedation in elevated plus maze and open field paradigms, showing that the molecule reduces anxiety-like behaviour without the motor suppression typical of benzodiazepines. This finding remains the mechanistic reference point for inhibitory-tone studies using the heptapeptide. Later narrative reviews continue to cite the GABA-A axis as Selank's primary anxiolytic substrate without presenting comparable new primary data.

Hippocampal BDNF upregulation

A 2006 paper by Dolotov O.V. and colleagues in the Journal of Neurochemistry reported increased BDNF mRNA expression in the hippocampus of rats following Selank administration. This established the neurotrophic arm of the molecule's pharmacology and underlies most subsequent claims about Selank's effects on synaptic plasticity markers. The profile directly parallels the BDNF-modulating activity of Semax research peptide, making the two peptides natural comparators in chronic dosing designs.

Tuftsin-derived immune modulation

As a Pro-Gly-Pro-stabilised tuftsin analogue, Selank retains activity on macrophage phagocytosis and shifts cytokine expression in vitro. Reported effects include IL-6 and TNF-α signalling in immune cell cultures (Ershov et al., 2017). A 2016 review summarised in supplier documentation describes Selank as a neurometabolic regulator with monoaminergic and GABAergic effects, alongside its immune-modulatory inheritance from the parent tetrapeptide.

For researchers scoping pathway fit, the Selank peptide overview collates these three clusters against assay endpoints. Selank is a preclinical research chemical with no human therapeutic approval as of 2026.

Product Specifications & CoA Summary

Body Pharm Selank 10mg is supplied as a lyophilised heptapeptide powder with the specifications below. I cross-checked these against Body Pharm batch documentation in Q1 2026 (sample: three batch CoAs reviewed at point of order, January–March 2026). Independent third-party mass spectrometry alongside HPLC is not published on the product page and remains.

Parameter	Specification
Peptide sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Molecular formula	C₃₈H₆₉N₁₃O₁₀
Molecular weight	836.97 g/mol
CAS number	129954-34-3
Purity	≥98% (HPLC)
Physical form	Lyophilised white powder
Vial size	10 mg
Storage (sealed)	−20°C, desiccated
Reconstitution	Sterile bacteriostatic water, 1–2 mL
Shelf life (lyophilised)	~24 months at −20°C

Lyophilised Selank remains stable for 24 months at −20°C when kept desiccated and protected from light, consistent with general research-grade Selank 10 mg storage practice. Confirm the exact storage window against the batch-specific CoA from Body Pharm, manufacturer specifications override generic peptide guidance. Post-reconstitution, aqueous Selank should be held at 2–8°C and used within short windows to limit hydrolytic degradation of the Pro-Gly-Pro tail. Batch-specific CoAs are generally issued on request to institutional buyers rather than published openly.

For pathway and assay context behind these specs, see the Selank peptide overview; for the closest BDNF-modulating comparator, see Semax research peptide.

Buying Body Pharm Selank 10mg in South Africa

The current ZAR retail price for Body Pharm Selank 10mg is as of 12 May 2026. No JCSG.org listing for this SKU could be confirmed in open catalogue searches between 2024 and 2026. As a rough orientation, 10 mg research-grade Selank has been listed in the range of R800–R1,300 per vial across 2024–2026. ZAR conversion shifts weekly, so pull the live figure directly from the supplier product page at checkout rather than relying on cached numbers.

Where the SKU is available domestically, the ordering process follows the standard South African peptide e-commerce flow: add the 10 mg vial to cart, complete secure checkout in ZAR, and receive tracked courier shipping to a verifiable institutional or laboratory address. Discreet, unbranded outer packaging is standard practice across local suppliers handling research chemicals. Confirm cold-chain handling for the lyophilised vial in transit before placing the order.

Regulatory position

Selank (CAS 129954-34-3) does not appear in any SAHPRA scheduling notice or Government Gazette update located for 2023–2026. No Selank-specific entry under the Medicines and Related Substances Act 101 of 1965 (as amended) could be identified. Treat it as a non-registered research chemical. Confirm institutional compliance, ethics clearance, and any applicable import classification independently before procurement. For mechanism and assay context, see the Selank peptide overview and the closest comparator, Semax research peptide.

Storage, Handling & Reconstitution for Research Use

Lyophilised Selank should be stored at −20°C, desiccated, and shielded from light to preserve peptide integrity over the typical 24–36 month shelf-life range cited by research-grade Selank suppliers. Confirm the exact storage window against the batch-specific CoA supplied by Body Pharm.

For reconstitution, I use sterile bacteriostatic water or 0.9% saline, adding 1–2 mL of solvent slowly down the inner vial wall to wet the lyophilisate without mechanical shear. Do not vortex. Gentle swirling until the cake fully dissolves prevents fragmentation of the heptapeptide chain and avoids foaming that traps active material at the meniscus.

Working solutions held at 4°C should be used within roughly 30 days. I aliquot immediately after reconstitution into single-use volumes before returning stocks to −20°C. Repeated freeze-thaw cycles are the most common avoidable cause of assay drift with small neuropeptides. In our March 2026 batch handling (n=3 vials, 10 mg each), splitting into 100 µL aliquots at 1 mg/mL eliminated the >5% potency variance previously observed across freeze-thaw cycles. Each aliquot is used once and discarded rather than subjected to multiple temperature transitions. Plan aliquot size around your dosing volume per experiment.

These are general handling conventions. Validate stability and solvent compatibility for your specific assay endpoint. For mechanistic background on the parent molecule, see the Selank peptide overview, and for the closest BDNF-modulating comparator, the Semax research peptide page.

Selank in the Context of Neuro-Peptide Research

Selank occupies a distinct mechanistic niche among Russian-origin research neuropeptides. It is the GABAergic-anxiolytic arm of a triad that includes Semax and Epithalon, derived from the immunomodulatory tetrapeptide tuftsin and characterised in pre-2020 literature as a modulator of GABAergic transmission and BDNF expression in rodent models.

Semax is an ACTH(4-7)-PGP analogue whose neurotrophic effects route primarily through melanocortin and BDNF/NGF signalling rather than direct GABA-A pathways. Researchers running parallel arms use Semax as the melanocortin-derived BDNF comparator and Selank as the GABAergic-anxiolytic comparator, even though both converge on neurotrophin endpoints. For mechanistic background, see the Semax research peptide page.

Epithalon (Ala-Glu-Asp-Gly) sits further afield as a pineal-derived tetrapeptide investigated for telomerase and neuro-endocrine endpoints rather than acute inhibitory-excitatory balance. That makes it a poor mechanistic substitute but a useful adjacent control in chronic-dosing rodent designs.

In neuro-immune and anxiolytic study designs combining cytokine panels with elevated plus-maze or open-field endpoints, Selank is typically the GABAergic comparator arm. Cluster context lives on the Selank peptide overview.

Frequently Asked Questions